Immune & Inflammation Peptides: The Complete Hub

Category: Pillar Hub Type: Hub Read Time: 28 minutes Author: Peptides.NYC Editorial Last Updated: 2026-05-19 URL: https://peptides.nyc/learn/hubs/immune

Overview

Immune peptides are one of the most misunderstood categories in the entire space. The common framing — "boost your immune system" — is exactly the wrong mental model. The peptides covered in this hub are not stimulants. They are immunomodulators: signaling molecules that aim to help a dysregulated immune system return toward a more normal set point.

That distinction matters enormously, especially for people with autoimmune conditions, chronic inflammatory response syndrome (CIRS), post-viral syndromes like long COVID, or biofilm-driven chronic infections. A "boost" pushes the immune system harder in whatever direction it is already going — including the wrong direction. Modulation, in contrast, is closer to a thermostat than a throttle.

This hub covers the full landscape of immune-relevant peptides: the thymic peptides (Thymosin alpha-1, Thymulin, Thymogen, Thymalin), the antimicrobial peptides (LL-37, Defensins), the α-MSH-derived anti-inflammatory KPV, the CIRS-specific VIP, the Russian immunological class (Imunofan, Splenopentin), and the gut-immune axis peptides (Larazotide, BPC-157, oral KPV).

We focus heavily on what immune peptides are good for, what they are not good for, and the autoimmune cautions that practitioners often gloss over. If you are searching for "immune peptides," "peptides for autoimmune," "peptides for chronic infections," "thymosin alpha-1," or "peptides for long COVID," start here — then drill down into the specific protocol guides linked throughout.

Immunomodulation vs Immunostimulation: The Critical Distinction

Peptides cluster firmly in the modulation category — but as you will see, "modulation" still has direction. Thymic peptides tend to enhance Th1 cell-mediated immunity. KPV tends to dampen NF-κB inflammation. VIP works on the autonomic-immune interface. None of them are blank checks.

The Immune Peptide Families

The immune peptide landscape is broad. Here is the high-level taxonomy you should understand before reading any single protocol guide.

A working mental model: thymic peptides tune the "command center" (T-cell maturation in the thymus). Antimicrobials act on pathogens directly. KPV and VIP dampen inflammatory signaling. The gut-immune axis stack rebuilds the largest immune surface in the body.

You will rarely use just one. Most serious immune protocols combine 2–4 peptides across families.

Thymosin Alpha-1 — The Workhorse

If there is a single "default" immune peptide, it is Thymosin alpha-1 (Tα1). It is the most clinically validated immune-modulating peptide we have. Marketed pharmaceutically as Zadaxin, it is approved or licensed in more than 35 countries for indications including hepatitis B, hepatitis C adjunct therapy, and certain cancer-related immune deficiencies. It is not FDA-approved in the United States, but it is one of the few peptides with serious phase II/III clinical trial data behind it.

Why Tα1 Is the Workhorse

• T-cell maturation: Promotes differentiation of immature thymocytes into mature CD4+ and CD8+ T cells
• Natural killer (NK) cell enhancement: Improves cytotoxic activity against virus-infected and abnormal cells
• Th1 polarization: Shifts immune responses toward Th1 (cell-mediated) immunity — useful for chronic viral infection
• Dendritic cell signaling: Improves antigen presentation
• Toll-like receptor modulation: Acts as a TLR agonist, particularly TLR9

Typical Use Cases

• Recurrent respiratory or viral infections
• Immunosenescence (age-related immune decline)
• Long COVID and post-viral fatigue syndromes
• Chronic Epstein-Barr or CMV reactivation
• Cancer adjuvant therapy (always provider-supervised)
• Hepatitis B/C adjunct

Typical Dosing (Educational Only)

Common research dosing is 1.6 mg subcutaneously, two to three times per week for acute use, or once to twice weekly for ongoing maintenance. Many practitioners run shorter "loading" phases at higher frequency followed by maintenance dosing.

Full deep dive: Thymosin Alpha-1 Protocol Guide

The Khavinson Thymic Peptides — Thymulin, Thymogen, Thymalin

Beyond Tα1, there is an entire Russian school of thymic peptide research, largely associated with Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. The three most commonly discussed are:

These are positioned as immune-regulating peptides for chronic viral infection, recurrent illness, post-surgical recovery, and immune aging. They are widely used in Russia and Eastern Europe but lack the large Western clinical trial portfolio Tα1 has.

What to Be Honest About

• Evidence quality is lower than for Tα1
• Many studies are older, smaller, and published in Russian-language journals
• Product variability is significant — sourcing matters even more than usual
• They are nonetheless used by experienced practitioners as alternatives or adjuncts to Tα1

Full deep dive: Thymulin, Thymogen & Thymalin Protocol Guide

LL-37 — The Antimicrobial

LL-37 (also called hCAP-18 after its precursor) is the only human cathelicidin antimicrobial peptide. It is one of your body's first-line innate immune defenses, produced by neutrophils, epithelial cells, and macrophages. It can directly disrupt bacterial, fungal, and certain viral membranes.

Why People Take It

• Biofilm penetration: Many chronic infections (sinus, gut, Lyme co-infections) hide inside biofilms that conventional antibiotics struggle to penetrate. LL-37 has biofilm-disruption activity.
• Broad antimicrobial action: Active against gram-positive, gram-negative, and certain fungal organisms
• Vitamin D connection: Endogenous LL-37 production is strongly upregulated by vitamin D. Optimizing 25-OH vitamin D (often 50–70 ng/mL range) is a prerequisite for any LL-37 protocol.
• Immune signaling: Beyond direct killing, LL-37 modulates chemotaxis and inflammatory signaling

IMPORTANT: Autoimmune Caution

LL-37 is a known autoantigen in several autoimmune conditions, including psoriasis, lupus, and rosacea. Anti-LL-37 antibodies are documented in subsets of these patients. Supplementing LL-37 in someone with active autoimmunity may worsen disease. Anyone with a history of psoriasis, lupus, rheumatoid arthritis, or unexplained autoimmune markers should have a provider review baseline autoimmune labs before considering LL-37.

This is not a peptide to self-experiment with if you have any autoimmune history.

Full deep dive: LL-37 Protocol Guide

KPV — The α-MSH-Derived Anti-Inflammatory

KPV is a tripeptide (Lysine-Proline-Valine) derived from the C-terminal sequence of α-MSH (alpha-melanocyte-stimulating hormone). It is small, simple, and surprisingly versatile.

Mechanism

• NF-κB suppression: Inhibits one of the master inflammatory signaling pathways
• Mast cell stabilization: Reduces histamine/cytokine release from mast cells
• Mucosal anti-inflammatory action: Strong activity in gut and oral mucosa
• Wound healing: Anti-inflammatory effects support wound resolution

Use Cases

• Inflammatory bowel disease (Crohn's, ulcerative colitis) adjunct — research interest is substantial
• Mast cell activation syndrome (MCAS) adjunct
• Skin inflammation (acne, eczema, psoriasis — though autoimmune skin conditions need provider oversight)
• Systemic inflammatory states with elevated hsCRP

Why KPV Pairs Well with Almost Everything

Because KPV is anti-inflammatory rather than directly immunostimulating, it stacks gracefully with thymic peptides (which can sometimes increase short-term inflammatory signaling as immune function rises) and with antimicrobials (where pathogen kill can release inflammatory debris).

Full deep dive: KPV Protocol Guide

VIP — The CIRS-Specific Peptide

Vasoactive Intestinal Peptide (VIP) is a 28-amino-acid neuropeptide with broad effects on the autonomic nervous system, vascular tone, and immune signaling. In the peptide community, however, VIP is most commonly associated with Dr. Ritchie Shoemaker's CIRS (Chronic Inflammatory Response Syndrome) protocol — specifically step 12, the final step.

CIRS Background

CIRS describes a chronic, multi-system inflammatory response to biotoxin exposure — most commonly water-damaged buildings (mold), Lyme disease, ciguatera, or post-COVID inflammation in some patients. The condition is characterized by elevated C4a, TGF-β1, MMP-9, and other inflammatory markers, along with low MSH and VIP.

Why VIP Is Step 12

VIP replacement is the final step in the Shoemaker Protocol because all earlier steps must be completed first — removal from exposure, cholestyramine binder therapy, MARCoNS eradication, antigliadin antibody normalization, androgen correction, ADH/osmolality correction, MMP-9 normalization, C3a normalization, C4a normalization, TGF-β1 normalization, and VEGF correction.

Using VIP before these prerequisites can drive inflammatory markers higher and worsen symptoms. This is not a peptide to use independently.

VIP is administered intranasally in the Shoemaker Protocol, typically starting at very low doses with strict monitoring of inflammatory labs.

Full deep dive: VIP & CIRS Protocol Guide

Russian Immune Peptides — Imunofan and Splenopentin

The Russian immunological school developed a distinct class of immune peptides used in oncology adjunct therapy, chronic viral disease, and post-surgical recovery.

These peptides illustrate a recurring theme in the Russian peptide tradition: short-course "kursy" (courses) of 5–10 days, often repeated 2–4 times per year, rather than continuous Western-style daily dosing.

The Western evidence base is thinner, but practitioners with international training increasingly incorporate them into protocols for patients who have plateaued on Tα1 alone.

Full deep dive: Splenopentin & Imunofan Protocol Guide

Autoimmune Considerations — CRITICAL

This section is the most important on the page. If you have an autoimmune condition or suspect one, read it twice.

Why Immune Peptides Are Risky in Autoimmunity

Most immune peptides — particularly the thymic class — enhance Th1 cell-mediated immunity. Many autoimmune conditions are already Th1-dominant:

• Hashimoto's thyroiditis (often Th1-dominant)
• Rheumatoid arthritis
• Multiple sclerosis
• Type 1 diabetes
• Crohn's disease
• Some forms of lupus (though lupus is more typically Th2)

Pushing Th1 harder in a Th1-dominant autoimmune disease can flare it. This is not theoretical — there are reports of Tα1 use coinciding with thyroid antibody elevation, joint flares, and neurological symptom worsening in susceptible individuals.

Specific Peptide Cautions

Required Before Starting Any Immune Peptide

• Baseline autoimmune screen: ANA, RF, anti-CCP, TPO, TG antibodies
• Thyroid panel: TSH, free T4, free T3
• Full inflammatory markers: hsCRP, ferritin, ESR
• Provider review — particularly an integrative or functional medicine MD/DO with peptide experience

If any of these are abnormal or if you have a family history of autoimmunity, the conversation shifts from "which immune peptide" to "should I use one at all."

The Gut-Immune Axis

More than 70% of the body's immune cells reside in or near the gut — primarily in the gut-associated lymphoid tissue (GALT) and the mucosal lining. Any conversation about immune function that ignores the gut is incomplete.

How the Gut-Immune Axis Breaks Down

1. Loss of barrier integrity ("leaky gut"): Tight junctions between intestinal epithelial cells loosen, allowing antigens and bacterial fragments (LPS) into circulation
2. Chronic low-grade inflammation: LPS in circulation triggers systemic inflammatory signaling
3. Dysbiosis: Loss of microbial diversity skews immune education
4. Mucosal immune dysfunction: Secretory IgA drops, oral tolerance breaks down

The Gut-Immune Peptide Stack

This stack is one of the few situations where three peptides at once is the standard rather than aggressive layering. Each addresses a different layer of the dysfunction: structural (Larazotide), regenerative (BPC-157), and inflammatory (KPV).

For deeper coverage, see the Larazotide Protocol, BPC-157 Complete Guide, and KPV Protocol Guide.

Sample Immune Protocols

The protocols below are illustrative frameworks based on commonly discussed approaches — not prescriptions. Always work with a qualified provider.

Every one of these assumes baseline labs, provider oversight, and quality-verified sourcing.

Use Cases

Recurrent Infections

Adults who get more than 3–4 colds, sinus infections, or UTIs per year often have suboptimal T-cell or NK cell function. Tα1 is the most evidence-backed option here.

Immunosenescence (Age-Related Immune Decline)

Thymic involution starts in adolescence and accelerates after 40. By 60, thymic output is a fraction of what it was at 20. Thymic peptides aim to partially compensate.

Chronic Lyme Adjunct

Lyme and co-infections (Babesia, Bartonella, Mycoplasma) can drive immune exhaustion and form biofilms. Tα1 supports T-cell function; LL-37 may help with biofilm disruption. This is always adjunct to evidence-based Lyme treatment, not a replacement.

Long COVID

A growing area of clinical interest. Persistent SARS-CoV-2 viral reservoirs, dysregulated T-cell responses, and ongoing inflammation are commonly observed. Tα1 has been studied in acute COVID with mixed but generally encouraging results; long COVID protocols often combine Tα1 with KPV for inflammation.

Autoimmune (Carefully)

Some practitioners use KPV cautiously in autoimmune patients for its anti-inflammatory profile. Thymic peptides are generally avoided. See the autoimmune section above.

Cancer Adjuvant (Provider-Supervised Only)

Tα1 has cancer adjuvant data in hepatocellular carcinoma, melanoma, and non-small-cell lung cancer settings. This is a domain for integrative oncologists, not self-experimenters.

What Immune Peptides Won't Do

This is where the marketing language and reality diverge most.

• Not a substitute for proper diagnostics. If you have unexplained recurrent infections, the workup (immunoglobulin levels, CD4/CD8 ratio, autoimmune screen, vitamin D, complement) comes first. Peptides without a diagnosis is guessing.
• Not for acute infections. A bacterial pneumonia needs antibiotics. A flu may need an antiviral. Sepsis needs the ICU. Peptides are not first-line acute care.
• Not a "boost." They will not make a healthy 25-year-old's immune system "stronger" in any meaningful sense. They normalize dysregulation; they don't supercharge baseline.
• Not a vaccine alternative. They do not generate antigen-specific immunity.
• Not a cure for autoimmunity. At best, certain peptides (KPV) may help modulate inflammation. They do not turn off the underlying immune dysregulation.
• Not a replacement for sleep, diet, stress management, or vitamin D. Endogenous immune function depends on these. No peptide compensates for chronic sleep deprivation or a 25 ng/mL vitamin D level.

Bloodwork & Monitoring

Anyone serious about immune peptides should have a baseline workup. The point is not to chase numbers — it is to know what you're working with and to detect adverse responses early.

Baseline Panel (Before Starting)

• CBC with differential — establishes baseline white cell lineages
• Comprehensive metabolic panel — liver and kidney function
• CD4/CD8 ratio (if available; often through specialty labs) — particularly relevant for chronic viral or post-COVID
• hsCRP — sensitive marker of low-grade inflammation
• Ferritin — both iron status and acute-phase reactant
• 25-OH Vitamin D — target 50–70 ng/mL for any LL-37 protocol
• Quantitative immunoglobulins (IgG, IgA, IgM, IgE) — rule out primary immunodeficiency
• IgG subclasses (1–4) if recurrent infections present
• Autoimmune screen: ANA, RF, anti-CCP, TPO, TG antibodies
• Thyroid panel: TSH, free T4, free T3, reverse T3
• EBV, CMV, HSV titers if chronic viral suspected
• Lyme + co-infection panel if exposure history

CIRS-Specific Labs (If Applicable)

C4a, C3a, TGF-β1, MMP-9, VEGF, MSH, ADH/osmolality, anti-gliadin antibodies, MARCoNS culture, VCS test. These are Shoemaker-Protocol-specific and require a CIRS-literate provider.

Follow-Up Cadence

• 4–6 weeks after starting: repeat hsCRP, CBC, and any abnormal baseline markers
• 12 weeks: full re-assessment
• Ongoing: every 3–6 months on maintenance, more frequently if symptoms shift

For a deeper template, see the Bloodwork Checklist.

Cycling Strategy

Immune peptides do not all share the same cycling logic.

The general principle: more potent immune signalers (LL-37, thymic peptides) benefit from periodic breaks. Anti-inflammatory peptides (KPV) tolerate continuous use better.

Top 10 Immune Peptide FAQ

Q: Will immune peptides make me get sick less? A: Possibly, if your baseline immune function is suboptimal. Tα1 in particular has data in reducing respiratory infection frequency in older adults. They will not eliminate illness in someone who is already healthy.

Q: Can I use Thymosin α-1 if I have Hashimoto's? A: This requires provider judgment. Tα1 enhances Th1 immunity, and Hashimoto's is often Th1-dominant. Many integrative practitioners avoid it in active Hashimoto's. Some use it cautiously with thyroid antibody monitoring. Do not self-decide.

Q: Is LL-37 safe to take long-term? A: Probably not. LL-37 is a known autoantigen in several autoimmune diseases, and long-term elevation may have unknown consequences. Most practitioners use it in short pulsed courses rather than continuously.

Q: What's the difference between Tα1 and the Russian thymic peptides? A: Tα1 has substantially more clinical trial evidence and is pharmaceutically approved in many countries. Thymulin/Thymogen/Thymalin are widely used in Russia but lack equivalent Western data. They may be useful alternatives or adjuncts but are not direct substitutes.

Q: Can immune peptides help with long COVID? A: Early clinical and anecdotal evidence is encouraging, particularly Tα1 + KPV combinations. Long COVID is heterogeneous, however — proper workup matters more than peptide choice.

Q: Do I need to take vitamin D with LL-37? A: Yes, optimization of vitamin D (target 50–70 ng/mL) is considered prerequisite. LL-37 endogenous production is vitamin-D-dependent, and the immune signaling context matters.

Q: Can I use immune peptides during an active infection? A: Acute bacterial or severe viral infections need conventional medical care first. Immune peptides are not a substitute for antibiotics or antivirals. They may be used adjunctively under provider supervision.

Q: How quickly do immune peptides work? A: Subjective improvements (energy, reduced infection frequency) often appear in 4–8 weeks. Lab markers (CD4/CD8, hsCRP) typically take 8–12 weeks to shift meaningfully.

Q: Is VIP something I can try on my own? A: No. VIP is the final step of a sequential 12-step CIRS protocol. Using it without completing the prerequisite steps can worsen inflammation. Find a Shoemaker-trained provider.

Q: Can I stack thymic peptides with antimicrobials like LL-37? A: Yes, this is a common combination for chronic biofilm-driven infections. Always with autoimmune screen first.

Featured Protocols on Peptides.NYC

• Thymosin Alpha-1 Protocol — the workhorse immune peptide
• Thymulin, Thymogen & Thymalin Protocol — the Russian thymic class
• LL-37 Protocol — antimicrobial cathelicidin with autoimmune cautions
• KPV Protocol — α-MSH-derived anti-inflammatory
• Defensins Protocol — mucosal antimicrobial peptides
• Splenopentin & Imunofan Protocol — Russian immune class
• Immune Support Protocol (The Stack) — multi-peptide foundational framework
• VIP & CIRS Protocol — Shoemaker Protocol step 12
• Larazotide Protocol — gut-immune axis tight-junction restoration

Related Content

• BPC-157 Complete Guide
• Bloodwork Checklist
• Doctor Conversation Script
• Peptide 101: What Are Peptides?
• Peptide Safety Guide
• Compounding Pharmacy Guide

Disclaimer: This content is for educational purposes only and is not medical advice. Immune peptides discussed in this hub are research compounds and most are not FDA-approved for human use in the United States. Thymosin alpha-1 (Zadaxin) is approved in many countries outside the US but not domestically.

Autoimmune Caveat — Read This Twice: Immune peptides are not generically "safe." Several — particularly the thymic class and LL-37 — can worsen autoimmune disease. Anyone with Hashimoto's, rheumatoid arthritis, multiple sclerosis, lupus, psoriasis, type 1 diabetes, or a family history of autoimmunity should have a baseline autoimmune workup and provider consultation before starting any immune peptide. "Modulation" is not the same as "harmless."

Consult a qualified healthcare provider — ideally one with peptide-specific experience and integrative medicine training — before starting any protocol. Self-experimentation with immune peptides is meaningfully riskier than with most other peptide categories.

Source: https://peptides.nyc/learn/hubs/immune